Dejan Juric, MD

Dejan Juric, MD is a pioneering oncologist specializing in targeted cancer therapies, with a focus on genetic alterations linked to therapy resistance. He is leading efforts to develop new agents targeting PIK3CA, a common mutation in metastatic breast cancer. Dr Juric received his medical degree from the University of Zagreb and completed postdoctoral research in cancer biology at Stanford University. He has held positions at top institutions, including Massachusetts General Hospital and Dana-Farber Cancer Institute, and continues to advance cancer treatment strategies through his leadership at the Termeer Center.